Literature DB >> 22651931

A pleckstrin homology-related domain in SHIP1 mediates membrane localization during Fcγ receptor-induced phagocytosis.

Andrew Ming-Lum1, Shaheen Shojania, Eva So, Erin McCarrell, Eileen Shaw, David Vu, Ida Wang, Lawrence P McIntosh, Alice L-F Mui.   

Abstract

SH2 domain-containing inositol-5'-phosphatase-1 (SHIP1) inhibits inflammation by hydrolyzing phosphoinositide-3'-kinase generated membrane phosphatidylinositol-3,4,5-trisphosphate (PIP(3)). Bioinformatic analysis of SHIP1 from multiple species revealed a pleckstrin homololgy-related (PH-R) domain, which we hypothesize mediates SHIP1's association with the membrane, a requirement for its biological function. Recombinant murine SHIP1 PH-R domain was subjected to biophysical and biochemical analysis. Residues K370 and K397 were found to be important for PH-R domain association with membrane PIP(3). Wild-type PH-R domain bound PIP(3) with 1.9 ± 0.2 nM affinity, while the affinity of a K370A/K397A substituted mutant was too low to measure. Wild-type (but not the K370A/K397A substituted) full-length SHIP1 protein, reconstitutes normal inhibition of Fcγ receptor-mediated phagocytosis when introduced into SHIP1(-/-) murine macrophages, reducing the number of phagocytic events by 2-fold as compared to SHIP1(-/-) cells. In fact, the PH-R-mediated membrane interaction appears to be a major mechanism by which SHIP1 is recruited to the membrane, since the K370A/K397A substitution reduced the recruitment of both full-length SHIP1 and the PH-R domain by ≥2-fold. We have previously shown that SHIP1 enzyme activity can be targeted for therapeutic purposes. The current studies suggest that molecules targeting the PH-R domain can also modulate SHIP1 function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22651931     DOI: 10.1096/fj.11-201475

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  9 in total

1.  Expression, Purification, Crystallisation and X-ray Crystallographic Analysis of a Truncated Form of Human Src Homology 2 Containing Inositol 5-Phosphatase 2.

Authors:  Johanne Le Coq; Luis Heredia Gallego; Daniel Lietha
Journal:  Protein J       Date:  2016-06       Impact factor: 2.371

Review 2.  Role of inhibitory signaling in peripheral B cell tolerance.

Authors:  Andrew Getahun
Journal:  Immunol Rev       Date:  2022-02-06       Impact factor: 12.988

3.  PtdIns(3,4)P2, Lamellipodin, and VASP coordinate actin dynamics during phagocytosis in macrophages.

Authors:  Fernando Montaño-Rendón; Glenn F W Walpole; Matthias Krause; Gerald R V Hammond; Sergio Grinstein; Gregory D Fairn
Journal:  J Cell Biol       Date:  2022-09-27       Impact factor: 8.077

Review 4.  Role of SHIP1 in cancer and mucosal inflammation.

Authors:  Sandra Fernandes; Sonia Iyer; William G Kerr
Journal:  Ann N Y Acad Sci       Date:  2013-03       Impact factor: 5.691

Review 5.  Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling.

Authors:  Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988

6.  Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities.

Authors:  Matthew D Blunt; Stephen G Ward
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

7.  Structural Insights into the Binding Propensity of Human SHIP2 SH2 to Oncogenic CagA Isoforms from Helicobacter pylori.

Authors:  Zi Wang; Yubao Shan; Ru Wang; Heng Zhou; Rui Hu; Ying Li; Jiang Zhu; Yunhuang Yang; Maili Liu
Journal:  Int J Mol Sci       Date:  2022-09-25       Impact factor: 6.208

8.  Activation/Inhibition of mast cells by supra-optimal antigen concentrations.

Authors:  Michael Huber
Journal:  Cell Commun Signal       Date:  2013-01-22       Impact factor: 5.712

9.  Role of inositol phospholipid signaling in natural killer cell biology.

Authors:  Matthew Gumbleton; William G Kerr
Journal:  Front Immunol       Date:  2013-03-06       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.